Accord Healthcare C/O UPD LEA Glen Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Accord Healthcare C/O UPD LEA Glen Pharmaceutical Import Records from India — 2 Products, $2.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Healthcare C/O UPD LEA Glen — Pharmaceutical Importer Profile (2026) | 2 Products, $2.2M Trade | TransData Nexus

Accord Healthcare C/O UPD LEA Glen

Pharmaceutical Importer · South Africa · CNS & Psychiatric Focus · $2.2M Total Trade · DGFT Verified

Accord Healthcare C/O UPD LEA Glen is a pharmaceutical importer based in South Africa with a total trade value of $2.2M across 2 products in 1 therapeutic categories. Based on 44 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Healthcare C/O UPD LEA Glen sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Accord Healthcare C/O UPD LEA Glen — Import Portfolio & Supplier Network

Accord Healthcare C/O UPD LEA Glen import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Healthcare C/O UPD LEA Glen?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$4.5M	296	100.0%

Accord Healthcare C/O UPD LEA Glen sources from 1 verified Indian supplier across 147 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Accord Healthcare C/O UPD LEA Glen Import?

Formulation	Value	Ships
Pharma drugs & medi sedalpha 100mcg/ML	$200.0K	4
Pharma drugs and medi cyfil 5 tadalafil5mg 2x14t as per	$150.0K	3
Pharma drugs & medi accord glimepiride	$139.8K	5
Pharma drugs & medi amtas-10 as per	$136.5K	5
Pharma drug&med:amtas-10 Each uncoated	$111.5K	4
Ph.dru.& med.: accord escitalopram tablets 20MG (Each tablet contains: escitalopram 20MG) [2x14t per	$100.0K	2
Ph.dru.& med.: accord escitalopram tablets 10MG (Each tablet contains: escitalopram 10MG) [2x14t per	$100.0K	2
Pharma drugs & medi:cyfil 20 tadalafil 20mg1x4t(ac-sa)	$97.2K	3
Pharm drug&med:rispacor 1 Each film coated tablet contains: risperidone ph. eur....1	$96.2K	3
Pharmaceutical drugs and medicine -	$91.0K	2
Pharma drugs & medi rispacor 1 as per	$86.2K	4
Pharma drugs & medi amtas-10 Each	$79.8K	3
Pharma drugs & medi rispacor 0.5 (3x10t-accord-sa) as per	$70.0K	3
Pharma drugs & medi naltima 50 as per	$67.3K	2
Pharmaceutical drugs & medicine-accord	$65.8K	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Citalopram	CNS & Psychiatric	$1.1M	22	0.4%	15
2	Escitalopram	CNS & Psychiatric	$1.1M	22	0.6%	9

Accord Healthcare C/O UPD LEA Glen imports 2 pharmaceutical products across 1 categories into South Africa totaling $2.2M.

Accord Healthcare C/O UPD LEA Glen — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Healthcare C/O UPD LEA Glen is a pharmaceutical importer and buyer based in South Africa, specializing in the procurement of finished pharmaceutical formulations. Operating from 14 Tamar Avenue, Roodepoort, 1709, Johannesburg, Gauteng, the company plays a pivotal role in enhancing the accessibility of essential medicines within the South African healthcare system.

As a subsidiary of Accord Healthcare, a global pharmaceutical entity, Accord Healthcare C/O UPD LEA Glen benefits from a robust international network and expertise in the development, manufacturing, and distribution of generic and biosimilar medicines. This affiliation enables the company to leverage a diverse portfolio spanning critical therapeutic areas such as oncology, cardiology, neurology, psychiatry, diabetes, pain management, and gastroenterology.

In the South African pharmaceutical distribution landscape, Accord Healthcare C/O UPD LEA Glen serves as a key importer, ensuring the availability of a wide range of high-quality medicines. Its operations are integral to meeting the healthcare needs of the South African population, particularly in the realm of generic and biosimilar products.

2Distribution Network

Accord Healthcare C/O UPD LEA Glen's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across South Africa. Operating from its facility at 14 Tamar Avenue, Roodepoort, the company coordinates logistics to facilitate timely and reliable supply chains.

The company's geographic coverage extends throughout South Africa, ensuring that essential medicines reach various regions, including urban and rural areas. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's affiliation with Accord Healthcare suggests access to a well-established global distribution infrastructure, potentially enhancing its logistics capabilities.

3Industry Role

In South Africa's pharmaceutical supply chain, Accord Healthcare C/O UPD LEA Glen functions primarily as an importer and distributor of finished pharmaceutical formulations. By sourcing a diverse range of generic and biosimilar medicines, the company ensures that healthcare providers have access to affordable and effective treatment options. This role is crucial in a market where the demand for cost-effective pharmaceuticals is significant.

The company's operations support the broader healthcare system by facilitating the availability of essential medicines, thereby contributing to improved patient outcomes and the overall efficiency of healthcare delivery in South Africa.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Healthcare C/O UPD LEA Glen

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Healthcare C/O UPD LEA Glen demonstrates a high degree of sourcing concentration, with all its pharmaceutical imports originating from a single supplier, Intas Pharmaceuticals Limited. This supplier dependency is evident from the total import value of $2.2 million USD across 44 shipments, with Intas Pharmaceuticals Limited accounting for $4.5 million USD over 296 shipments.

This concentrated sourcing strategy may offer benefits such as streamlined procurement processes and potentially favorable pricing agreements. However, it also introduces risks associated with over-reliance on a single supplier, including vulnerability to supply chain disruptions, price fluctuations, and changes in supplier policies.

The shipment data indicates a stable relationship between Accord Healthcare C/O UPD LEA Glen and Intas Pharmaceuticals Limited, as evidenced by the consistent volume of imports over the years. Nonetheless, the lack of supplier diversification suggests that the company may need to develop contingency plans to mitigate potential risks associated with this sourcing concentration.

2Supply Chain Resilience

Accord Healthcare C/O UPD LEA Glen's supply chain resilience is closely tied to its exclusive sourcing from Intas Pharmaceuticals Limited. While this concentrated approach may lead to operational efficiencies, it also exposes the company to risks such as supply chain disruptions, regulatory changes, or geopolitical issues affecting the supplier.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

In South Africa, the primary regulatory authority overseeing pharmaceutical imports is the South African Health Products Regulatory Authority (SAHPRA). SAHPRA is responsible for ensuring the safety, efficacy, and quality of health products, including medicines, medical devices, and in vitro diagnostics.

Key legislation governing pharmaceutical imports includes the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), which provides the legal framework for the regulation of medicines and related substances in South Africa. This Act outlines the requirements for the registration, importation, and distribution of medicines within the country.

The marketing authorization pathway for Indian generics involves obtaining approval from SAHPRA, which includes submitting comprehensive documentation demonstrating the product's quality, safety, and efficacy. This process ensures that imported generics meet the standards required for the South African market.

2Import Licensing & GMP

Import licensing requirements in South Africa stipulate that all pharmaceutical products must be registered with SAHPRA before they can be imported and marketed. This registration process involves providing detailed information about the product, including its composition, manufacturing process, and clinical data.

Accord Healthcare C/O UPD LEA Glen — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Healthcare C/O UPD LEA Glen's product category focus on Central Nervous System (CNS) and Psychiatric medications, particularly Citalopram and Escitalopram, reflects a strategic alignment with prevalent health concerns in South Africa. The significant import values of $1.1 million USD each for Citalopram and Escitalopram underscore the substantial demand for these medications.

The market demand for these products is driven by the high prevalence of mental health conditions, including depression and anxiety disorders, within the South African population. By focusing on these therapeutic areas, Accord Healthcare C/O UPD LEA Glen addresses a critical need for accessible and effective psychiatric treatments.

2Sourcing Profile

Accord Healthcare C/O UPD LEA Glen's sourcing strategy is characterized by a strong reliance on Indian manufacturers, particularly Intas Pharmaceuticals Limited. This approach leverages India's established reputation for producing high-quality generic and biosimilar medicines at competitive prices.

The company's preference for sourcing from India aligns with its commitment to providing affordable and effective treatments to the South African market. By partnering with reputable Indian manufacturers

TransData Nexus Research · DGFT trade data analysis

Frequently Asked Questions — Accord Healthcare C/O UPD LEA Glen

What products does Accord Healthcare C/O UPD LEA Glen import from India?

Accord Healthcare C/O UPD LEA Glen imports 2 pharmaceutical products across 1 categories. Top imports: Citalopram ($1.1M), Escitalopram ($1.1M).

Who supplies pharmaceuticals to Accord Healthcare C/O UPD LEA Glen from India?

Accord Healthcare C/O UPD LEA Glen sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $4.5M).

What is Accord Healthcare C/O UPD LEA Glen's total pharmaceutical import value?

Accord Healthcare C/O UPD LEA Glen's total pharmaceutical import value from India is $2.2M, based on 44 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Healthcare C/O UPD LEA Glen focus on?

Accord Healthcare C/O UPD LEA Glen imports across 1 categories. The largest: CNS & Psychiatric (100.0%).

Get Full Accord Healthcare C/O UPD LEA Glen Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.